University Medical Center Hamburg-Eppendorf
University Medical Center Hamburg-Eppendorf is recorded as a service provider in 18 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 18 of 18 trials · Latest update first
Randomized study to compare first-line treatment with either continuous or intermittent cetuximab plus FOLFIRI in patients with RAS/BRAF-wild-type metastatic colorectal cancer (mCRC): AIO-KRK-0524 / FIRE-11
Sponsor Charite Universitaetsmedizin Berlin KöR
- Start (EU)
- Not reported
- Latest update
- Estimated end
- Not reported
International cooperative prospective study for children and adolescents with standard risk ALK-positive anaplastic large cell lymphoma (ALCL) estimating the efficacy of Vinblastine
Sponsor GPOH gGmbH
- Start (EU)
- Latest update
- Estimated end
- Not reported
Early treatment of Atrial fibrillation for Stroke prevention Trial in acute STROKE (EAST-STROKE)
Sponsor University Medical Center Hamburg-Eppendorf
- Start (EU)
- Latest update
- Estimated end
Thrombolysis with Tenecteplase for Acute Ischemic Stroke in Patients taking Direct Oral Anticoagulants – a multicentre randomised placebo-controlled clinical trial
Sponsor University Medical Center Hamburg-Eppendorf
- Start (EU)
- Latest update
- Estimated end
- Not reported
ALLTogether1 - A Treatment Study Protocol of the ALLTogether Consortium for Children and Young Adults (0-45 Years of Age) with Newly Diagnosed Acute Lymphoblastic Leukaemia (ALL)
Sponsor Karolinska University Hospital
- Start (EU)
- Latest update
- Estimated end
Reduction of SystemiC Inflammation after ischemic stroke by intravenous DNase administration (ReSCInD)
Sponsor Klinikum der Universitaet Muenchen AöR
- Start (EU)
- Latest update
- Estimated end
- Not reported
SIOP-HRMB: An international prospective trial on clinically high-risk medulloblastoma (HR-MB) in patients older than 3 years.
Sponsor The University Of Birmingham
- Start (EU)
- Latest update
- Estimated end
Pembrolizumab in combination with lenvatinib in patients with recurrent, persistent, metastatic or locally advanced vulvar cancer not amenable to curative surgery or radiotherapy
Sponsor AGO Research GmbH
- Start (EU)
- Latest update
- Estimated end
- Not reported
A PHASE 3 RANDOMIZED, OPEN-LABEL TRIAL OF SELINEXOR, POMALIDOMIDE, AND DEXAMETHASONE (SPd) VERSUS ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EloPd) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM)
Sponsor European Myeloma Network B.V.
- Start (EU)
- Latest update
- Estimated end
A PHASE I/II STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MEBENDAZOLE IN COMBINATION WITH LOW-DOSE ARA-C IN ELDERLY PATIENTS WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA (MAIL)
Sponsor University Medical Center Hamburg-Eppendorf
- Start (EU)
- Not reported
- Latest update
- Estimated end
- Not reported
ZANGEA – Phase II Study of Zanidatamab in Combination with Pembrolizumab and Chemotherapy in HER2 and PD-L1 Positive Metastatic Gastroesophageal Adenocarcinoma (GEA) Patients
Sponsor Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH
- Start (EU)
- Latest update
- Estimated end
- Not reported
CATALINA-2: A Phase 2 Study Evaluating the Efficacy and Safety of TORL-1-23 in Women With Advanced Platinum-Resistant Epithelial Ovarian Cancer (Including Primary Peritoneal and Fallopian Tube Cancers) Expressing Claudin 6 (CLDN6)
Sponsor Torl Biotherapeutics LLC
- Start (EU)
- Latest update
- Estimated end
Early Reperfusion Therapy with Intravenous Thrombolysis for Recovery of VISION in Acute Central Retinal Artery Occlusion (REVISION) - A double-blind randomized placebo-controlled phase III trial
Sponsor Universitaetsklinikum Tuebingen AöR
- Start (EU)
- Latest update
- Estimated end
- Not reported
A Phase 2b, multicenter, randomized, double-blind study of safety and efficacy of TAK-755 (rADAMTS13) with minimal to no plasma exchange (PEX) in the treatment of immune-mediated thrombotic thrombocytopenic purpura (iTTP)
Sponsor Takeda Development Center Americas Inc.
- Start (EU)
- Latest update
- Estimated end
Multicenter, Phase Ib/IIa Study on the Safety and Efficacy of Autologous Peptide-coupled Red Blood Cells in Patients with Relapsing Remitting Multiple Sclerosis
Sponsor Cellerys AG
- Start (EU)
- Latest update
- Estimated end
Prospective, randomized study concerning personalized medicine with Pentaglobin® after interventional infectious source control in peritonitis patients
Sponsor Universitaetsklinikum Aachen AöR
- Start (EU)
- Latest update
- Estimated end
- Not reported
Comparison of neurocognitive outcome in two standard regimen for treatment of low-risk medulloblastoma (COGNITO-MB)
Sponsor GPOH gGmbH
- Start (EU)
- Not reported
- Latest update
- Estimated end
- Not reported
Treating Nightmares in Posttraumatic Stress Disorder with the α-adrenergic Agents Clonidine and Doxazosin: A Randomized-Controlled Feasibility Study - ClonDoTrial
Sponsor Charite Universitaetsmedizin Berlin KöR
- Start (EU)
- Latest update
- Estimated end
- Not reported
Questions about this trial experience
What services are recorded for University Medical Center Hamburg-Eppendorf?
The 2026-10-09 snapshot links University Medical Center Hamburg-Eppendorf to 18 distinct CTIS trials. Recorded services include Data management, Laboratory services, Statistical analysis, Medical expertise, among 23 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for University Medical Center Hamburg-Eppendorf?
The most frequently recorded therapeutic areas are Neurology, Haematological Malignancies, Solid Tumor Oncology, Cardiology. Recorded phases include Phase 2, Phase 3, Phase 4. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to University Medical Center Hamburg-Eppendorf conducted?
The linked trials record locations in 20 countries, including Germany, Netherlands, Austria, Belgium, Spain. These are trial locations, not confirmed office locations or countries where University Medical Center Hamburg-Eppendorf delivered services.
What can this page tell me about University Medical Center Hamburg-Eppendorf's trial experience?
Browse 18 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under University Medical Center Hamburg-Eppendorf. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- University Medical Center Hamburg-Eppendorf